Amgen Inc. (AMGN)
NASDAQ: AMGN · Real-Time Price · USD
388.16
+8.83 (2.33%)
At close: Feb 27, 2026, 4:00 PM EST
388.00
-0.16 (-0.04%)
After-hours: Feb 27, 2026, 7:47 PM EST
Amgen Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Operating Revenue | 35,148 | 32,026 | 26,910 | 24,801 | 24,297 | Upgrade
|
| Other Revenue | 1,603 | 1,398 | 1,280 | 1,522 | 1,682 | Upgrade
|
| Revenue | 36,751 | 33,424 | 28,190 | 26,323 | 25,979 | Upgrade
|
| Revenue Growth (YoY) | 9.95% | 18.57% | 7.09% | 1.32% | 2.18% | Upgrade
|
| Cost of Revenue | 10,737 | 10,458 | 7,795 | 6,376 | 6,454 | Upgrade
|
| Gross Profit | 26,014 | 22,966 | 20,395 | 19,947 | 19,525 | Upgrade
|
| Selling, General & Admin | 7,050 | 7,096 | 5,692 | 5,414 | 5,368 | Upgrade
|
| Research & Development | 7,272 | 5,964 | 4,784 | 4,434 | 4,819 | Upgrade
|
| Other Operating Expenses | 118 | 230 | 96 | 1 | 187 | Upgrade
|
| Operating Expenses | 14,440 | 13,290 | 10,572 | 9,849 | 10,374 | Upgrade
|
| Operating Income | 11,574 | 9,676 | 9,823 | 10,098 | 9,151 | Upgrade
|
| Interest Expense | -3,163 | -3,665 | -4,100 | -1,533 | -1,208 | Upgrade
|
| Interest & Investment Income | 408 | 510 | 1,225 | 127 | 11 | Upgrade
|
| Currency Exchange Gain (Loss) | 221 | -75 | 42 | -233 | -245 | Upgrade
|
| Other Non Operating Income (Expenses) | 178 | 512 | 1,128 | -180 | 978 | Upgrade
|
| EBT Excluding Unusual Items | 9,218 | 6,958 | 8,118 | 8,279 | 8,687 | Upgrade
|
| Merger & Restructuring Charges | -1,300 | -2,400 | -1,143 | -30 | - | Upgrade
|
| Gain (Loss) on Sale of Investments | 1,988 | -146 | 1,438 | -479 | -474 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | -567 | - | Upgrade
|
| Asset Writedown | -1,200 | - | -783 | - | - | Upgrade
|
| Other Unusual Items | 270 | 197 | 225 | 143 | -7 | Upgrade
|
| Pretax Income | 8,976 | 4,609 | 7,855 | 7,346 | 6,701 | Upgrade
|
| Income Tax Expense | 1,265 | 519 | 1,138 | 794 | 808 | Upgrade
|
| Net Income | 7,711 | 4,090 | 6,717 | 6,552 | 5,893 | Upgrade
|
| Net Income to Common | 7,711 | 4,090 | 6,717 | 6,552 | 5,893 | Upgrade
|
| Net Income Growth | 88.53% | -39.11% | 2.52% | 11.18% | -18.87% | Upgrade
|
| Shares Outstanding (Basic) | 538 | 537 | 535 | 538 | 570 | Upgrade
|
| Shares Outstanding (Diluted) | 542 | 541 | 538 | 541 | 573 | Upgrade
|
| Shares Change (YoY) | 0.18% | 0.56% | -0.56% | -5.58% | -2.88% | Upgrade
|
| EPS (Basic) | 14.33 | 7.62 | 12.56 | 12.18 | 10.34 | Upgrade
|
| EPS (Diluted) | 14.23 | 7.56 | 12.49 | 12.11 | 10.28 | Upgrade
|
| EPS Growth | 88.23% | -39.47% | 3.14% | 17.80% | -16.49% | Upgrade
|
| Free Cash Flow | 8,100 | 10,394 | 7,359 | 8,785 | 8,381 | Upgrade
|
| Free Cash Flow Per Share | 14.95 | 19.21 | 13.68 | 16.24 | 14.63 | Upgrade
|
| Dividend Per Share | 9.520 | 9.000 | 8.520 | 7.760 | 7.040 | Upgrade
|
| Dividend Growth | 5.78% | 5.63% | 9.79% | 10.23% | 10.00% | Upgrade
|
| Gross Margin | 70.78% | 68.71% | 72.35% | 75.78% | 75.16% | Upgrade
|
| Operating Margin | 31.49% | 28.95% | 34.85% | 38.36% | 35.23% | Upgrade
|
| Profit Margin | 20.98% | 12.24% | 23.83% | 24.89% | 22.68% | Upgrade
|
| Free Cash Flow Margin | 22.04% | 31.10% | 26.11% | 33.37% | 32.26% | Upgrade
|
| EBITDA | 16,617 | 15,157 | 13,755 | 13,358 | 12,549 | Upgrade
|
| EBITDA Margin | 45.21% | 45.35% | 48.79% | 50.75% | 48.30% | Upgrade
|
| D&A For EBITDA | 5,043 | 5,481 | 3,932 | 3,260 | 3,398 | Upgrade
|
| EBIT | 11,574 | 9,676 | 9,823 | 10,098 | 9,151 | Upgrade
|
| EBIT Margin | 31.49% | 28.95% | 34.85% | 38.36% | 35.23% | Upgrade
|
| Effective Tax Rate | 14.09% | 11.26% | 14.49% | 10.81% | 12.06% | Upgrade
|
| Revenue as Reported | 36,751 | 33,424 | 28,190 | 26,323 | 25,979 | Upgrade
|
| Advertising Expenses | 963 | 987 | 647 | 841 | 843 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.